Patients beginning lung cancer treatment demonstrated a high prevalence of atherosclerosis, which suggests that they may benefit from calcium scoring, new data showed. According to a presentation ...

The Amyloidosis Program at University of Utah Health and Huntsman Cancer Institute is one of the few programs in the United States specifically designed to treat amyloidosis and provide ...

Multiple myeloma and AL amyloidosis are conditions linked to plasma cells in the bone marrow. Multiple myeloma (MM) is a cancer affecting the plasma cells, which are mostly in the bone marrow. MM ...

Amyloidosis is a complex disease and the program at Huntsman Cancer Institute (HCI) uses a collaborative approach to provide comprehensive medical care. Researchers are tirelessly trying to find new ...

BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2 safety and tolerability data for CAEL-101, a potentially ...

Credit: Getty Images. NXC-201 is an autologous BCMA-targeted investigational chimeric antigen receptor T cell therapy. The Food and Drug Administration (FDA) has granted Orphan Drug designation to NXC ...

Healio spoke with Joban Vaishnav, MD, director of the Johns Hopkins Comprehensive Amyloidosis Center, about the process of diagnosing amyloidosis, the importance of multidisciplinary care in patients ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III trials. A light chain depleter antibody, anselamimab was being investigated in ...

Amyloid heart disease occurs when amyloid fibrils build up in the heart, making it more difficult for the heart to pump blood around the body. Eventually, this can lead to heart failure. People can ...